Prognostic factors in non-small cell lung cancer patients with postoperative recurrence following third-generation chemotherapy

Anticancer Research

Volumn 30, Issue 4, 2010, Pages 1311-1315

  Yamazaki, Koji ^a   Sugio, Kenji ^a   Yamanaka, Takeharu ^a   Hirai, Fumihiko ^a   Osoegawa, Atsushi ^a   Tagawa, Tetsuzo ^a   Fukuyama, Seiichi ^a   Wataya, Hiroshi ^a   Seto, Takashi ^a   Ichinose, Yukito ^a  

^a NATIONAL KYUSHU CANCER CENTER   (Japan)

Author keywords

Chemotherapy; Lung cancer; Postoperative recurrence; Survival analysis

Indexed keywords

DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; GEFITINIB; GEMCITABINE; IRINOTECAN; NAVELBINE; PACLITAXEL;

ADRENAL GLAND; ADRENAL METASTASIS; ADULT; AGED; ARTICLE; BLOOD CELL COUNT; BLOOD CHEMISTRY; BONE METASTASIS; BONE SCINTISCANNING; BRAIN METASTASIS; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CELL TYPE; CIGARETTE SMOKING; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DISEASE FREE INTERVAL; ELECTROCORTICOGRAPHY; FEMALE; GENDER; GROUPS BY AGE; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER METASTASIS; LUNG ADENOCARCINOMA; LUNG METASTASIS; LUNG NON SMALL CELL CANCER; LUNG RESECTION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROGNOSIS; SMOKING; SURVIVAL TIME; THORAX RADIOGRAPHY; UNIVARIATE ANALYSIS;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; COMBINED MODALITY THERAPY; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SURVIVAL RATE;

EID: 77953795906     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Khuri FR, Herbst RS and Fossella FV: Emerging therapies in non-small cell lung cancer. Ann Oncol 12: 739-744, 2001.
2. Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon JP and Vansteenkiste J: Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small cell lung cancer. N Engl J Med 350: 351-360, 2004. (Pubitemid 38101630)
3. Winton T, Livingston R, Johnson D, Rigas J, Johnston M, Butts C, Cormier Y, Goss G, Inculet R, Vallieres E, Fry W, Bethune D, Ayoub J, Ding K, Seymour L, Graham B, Tsao MS, Gandara D, Kesler K, Demmy T and Shepherd F: Vinorelbine plus cisplatin vs. observation in resected non-small cell lung cancer. N Engl J Med 352: 2589-2597, 2005.
4. Nesbitt JC, Putnam JB Jr, Walsh GL, Roth JA and Mountain CF: Survival in early-stage non-small cell lung cancer. Ann Thorac Surg 60: 466-472, 1995.
5. Yana T, Takada M, Origasa H, Ijima T, Yamamoto N and Nakagawa K: New chemotherapy agent plus platinum for advanced non-small cell lung cancer: a meta-analysis. Proc Am Soc Clin Oncol 21: 328a, 2004.
6. Baggstrom MQ, Stinchcombe TE, Fried DB, Poole C, Hensing TA and Socinski MA: Third-generation chemotherapy agents in the treatment of advanced non-small cell lung cancer: a meta-analysis. J Thorac Oncol 2: 845-853, 2007.
7. Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY, Nishiwaki Y, Vansteenkiste J, Kudoh S, Rischin D, Eek R, Horai T, Noda K, Takata I, Smit E, Averbuch S, Macleod A, Feyereislova A, Dong RP and Baselga J: Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small cell lung cancer (The IDEAL 1 Trial). J Clin Oncol 21: 2237-2246, 2003. (Pubitemid 46621858)
8. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R, van Kooten M, Dediu M, Findlay B, Tu D, Johnston D, Bezjak A, Clark G, Santabarbara P and Seymour L: Erlotinib in previously treated non-small cell lung cancer. N Engl J Med 353: 123-132, 2005.
9. Mitsudomi T and Yatabe Y: Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. Cancer Sci 98: 1817-1824, 2007.
10. Sugio K, Uramoto H, Onitsuka T, Mizukami M, Ichiki Y, Sugaya M, Yasuda M, Takenoyama M, Oyama T, Hanagiri T and Yasumoto K: Prospective phase II study of gefitinib in non-small cell lung cancer with epidermal growth factor receptor gene mutations. Lung Cancer 64: 314-318, 2009.
11. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, Nishiwaki Y, Ohe Y, Yang JJ, Chewaskulyong B, Jiang H, Duffield EL, Watkins CL, Armour AA and Fukuoka M: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361: 947-957, 2009.
12. Sobin LH and Wittenkind C: TNM Classification of Malignant Tumors (5th ed.). New York: Wiley-Liss, 1997.
13. Martini N and Melamed MR: Multiple primary lung cancers. J Thorac Cardiovasc Surg 70: 606-612, 1975.
14. Ichinose Y, Yano T, Yokoyama H, Inoue T, Asoh H, Tayama K and Takanashi N: Postrecurrence survival of patients with non-small-cell lung cancer undergoing a complete resection. J Thorac Cardiovasc Surg 108: 158-161, 1994. (Pubitemid 24224272)
15. Mitsudomi T, Nishioka K, Maruyama R, Saitoh G, Hamatake M, Fukuyama Y, Yaita H, Ishida T and Sugimachi K: Kinetic analysis of recurrence and survival after potentially curative resection of non-small cell lung cancer. J Surg Oncol 63: 159-165, 1996.
16. Yoshino I, Yohena T, Kitajima M, Ushijima C, Nishioka K, Ichinose Y and Sugimachi K: Survival of non-small cell lung cancer patients with postoperative recurrence at distant organs. Ann Thorac Cardiovasc Surg 7: 204-209, 2001.
17. Williams BA, Sugimura H, Endo C, Nichols FC, Cassivi SD, Allen MS, Pairolero PC, Deschamps C and Yang P: Predicting postrecurrence survival among completely resected non-small cell lung cancer patients. Ann Thorac Surg 81: 1021-1027, 2006. (Pubitemid 43247679)
18. Sugimura H, Nichols FC, Yang P, Allen MS, Cassivi SD, Deschamps C, Williams BA and Pairolero PC: Survival after recurrent non-small cell lung cancer after complete pulmonary resection. Ann Thorac Surg 83: 409-417, 2007.
19. Asmis TR, Ding K, Seymour L, Shepherd FA, Leighl NB, Winton TL, Whitehead M, Spaans JN, Graham BC and Goss GD: Age and comorbidity as independent prognostic factors in the treatment of non-small cell lung cancer: a review of National Cancer Institute of Canada Clinical Trials Group trials. J Clin Oncol 26: 54-59, 2008.
20. Morita S, Okamoto I, Kobayashi K, Yamazaki K, Asahina H, Inoue A, Hagiwara K, Sunaga N, Yanagitani N, Hida T, Yoshida K, Hirashima T, Yasumoto K, Sugio K, Mitsudomi T, Fukuoka M and Nukiwa T: Combined survival analysis of prospective clinical trials of gefitinib for non-small cell lung cancer with EGFR mutations. Clin Cancer Res 15: 4493-4498, 2009.
21. Tanvetyanon T, Robinson LA, Schell MJ, Strong VE, Kapoor R, Coit DG and Bepler G: Outcomes of adrenalectomy for isolated synchronous versus metachronous adrenal metastases in non-small cell lung cancer: a systematic review and pooled analysis. J Clin Oncol 26: 1142-1147, 2008.